Metabolism Molecular: Mmetụta ọgwụgwọ nke NMN supplementation na polycystic ovary syndrome

N'ime afọ ndị na-adịbeghị anya, na mmụba nke ndụ na-adịghị mma na nrụgide mmekọrịta ọha na eze na-arịwanye elu nke ụmụ nwanyị, ọnụ ọgụgụ nke polycystic ovary syndrome (PCOS) na-apụtawanye ìhè.Nnyocha ndị mba ọzọ egosila na ọnụ ọgụgụ nke polycystic ovary syndrome (PCOS) na ụmụ nwanyị nọ n'afọ ime dị elu dị ka 6% -15 %, ebe na China, ọnụ ọgụgụ ya dị elu dị ka 6% -10 %.

Polycystic ovary syndrome bụ ọrịa na-emekarị na ụmụ nwanyị na-amụ nwa n'ihi ọrịa endocrine.A na-egosipụtakarị ya na glucose na-adịghị mma na metabolism lipid na arụ ọrụ ịmụ nwa.Usoro nyocha nke ụlọ ọgwụ bụ nsogbu nke ọkwa hormone (oke androgen), na-eme ka nsogbu nke ovulation na mgbanwe polycystic ovarian, na ọtụtụ ndị inyom nwere PC COS nwere njirimara metabolic ọjọọ, dị ka insulin resistance, oke ibu, na hepatic steatosis.

Ugbu a, enwere ọgwụ ole na ole maka ọgwụgwọ PCOS.Usoro a na-ahụkarị bụ ịkwalite PCOS site n'ịchụso na igbochi oke androgen na ọgwụ mgbochi androgen.Otú ọ dị, e nwekwara ihe àmà na-egosi na ọgwụ anti-androgen nwere ike imeju toxicity, ya mere ojiji ha nwere oke.Ya mere, ọ dị ezigbo mkpa ịchọ ihe okike na-enweghị mmetụta ọ bụla iji dochie ọgwụ ndị dị ugbu a.

Nnyocha e mere n'oge na-adịbeghị anya nke Mahadum New South Wales dị n'Australia chọpụtara na ọrịa polycystic ovary na-emetụta ụkọ NAD +, na e bipụtara nsonaazụ nyocha na akwụkwọ akụkọ sayensị "Molecular Metabolism" .

Ndị otu nyocha ahụ buru ụzọ tinye dihydrotestosterone (DHT) subcutaneously n'ime ụmụ oke ụmụ oke tupu na mgbe ha tolitere iji guzobe ụdị òké PC COS, na mgbe izu 8 gasịrị nke ọgwụgwọ NMN, insulin na-ebu ọnụ na nchọpụta nguzogide insulin HOMA, ule nnabata glucose, abụba Mgbe ule ndị dị otú ahụ gasịrị. dị ka histomorphometry, ihe ndekọ ọnụ ọgụgụ na-egosi:

1. N MN na-eweghachi ọkwa N AD + na akwara nke ụmụ oke P COS
chọpụtara na ọkwa NAD + dị na akwara nke ụmụ oke PCOS belatara nke ukwuu, na nri NMN weghachiri ọkwa NAD na akwara nke ụmụ oke PCOS.

2. NMN na-eme ka nguzogide insulin na oke ibu na oke PCOS
Insulin nke DHT butere ihe karịrị okpukpu abụọ n'ime oke PCOS na-ebu ọnụ, ikekwe na-egosipụta nguzogide insulin.Site n'inye NMN nri, achọpụtara na ọkwa insulin na-ebu ọnụ eweghachiri n'ogo dị nso nke oke oke.Na mgbakwunye, arọ ahụ nke ụmụ oke PCOS mụbara site na 20%, oke abụba mụbara nke ukwuu.

3. NMN na-eweghachi ntinye lipid hepatic na-adịghị mma na ụmụ oke PCOS
Otu n'ime njirimara polycystic ovary syndrome bụ ntinye nke lipid n'ime imeju na ntinye nke imeju nwere abụba.Mgbe ọ nwụsịrị NMN, ọ fọrọ nke nta ka ọ ghara ikpochapụ nsị lipid imeju na-adịghị mma na ụmụ oke PCOS, na triglycerides na imeju laghachiri n'ogo nke ụmụ oke nkịtị.

N'ikpeazụ, ọkwa NAD + dị na akwara PCOS belatara nke ukwuu, na ọnọdụ PCOS belatara site n'ịgbakwụnye NMN, ihe mmalite nke NAD +, nke nwere ike ịbụ usoro ọgwụgwọ ọgwụgwọ maka ọgwụgwọ PCOS.

ntụaka:
[1].Aflatounian A, Paris VR, Richani D, Edwards MC, Cochran BJ, Ledger WL, Gilchrist RB, Bertoldo MJ, Wu LE, Walters KA.Mbelata akwara NAD + na hyperandrogenism PCOS ụdị òké: Ọrụ enwere ike na dysregulation metabolic.Mol Metab.2022 Septemba 9;65:101583 .doi: 10.1016/j.molmet.2022.101583.Epub tupu ebipụta.PMID: 36096453.